BONE MARROW-DERIVED MESENCHYMAL STEM CELLS (MSCS) AS A SELECTIVE DELIVERY VEHICLE FOR A PSA-ACTIVATED PROTOXIN FOR ADVANCED PROSTATE CANCER

The Johns Hopkins University

Investigators